Biomarker sub study of the phase II study of trastuzumab and pertuzumab combination therapy for HER2 amplified advanced solid tumors
Not Applicable
- Conditions
- HER2 amplified solid tumor
- Registration Number
- JPRN-UMIN000037425
- Lead Sponsor
- Tokyo Medical and Dental University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
According to Phase II study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relationships among genomic alterations and response
- Secondary Outcome Measures
Name Time Method